FLT4 and gastric cancer: Rosiglitazone [87], a peroxisome proliferator-activated receptor γ (PPARγ) agonist, has shown promising suppressive effect on lymphangiogenesis by concurrently downregulating the expression of VEGF-C and VEGFR-3 in GC xenograft mice models [93].